Clinical Trial

Proteomic Biomarker Identification in Age-Related Macular Degeneration, Diabetic Retinopathy and Retinal Detachment

Study acronym: PRO Project
Recruiting
View on ClinicalTrials.gov →
Summary
This prospective interventional translational study aims to identify and validate protein biomarkers associated with major ophthalmological diseases, including age-related macular degeneration, diabetic retinopathy (DR), and retinal detachment (RD). A total of approximately 260 participants (cases and controls) will be enrolled at a single center. Biological samples, including peripheral blood, tears, aqueous humor, vitreous humor, and subretinal fluid, will be collected during routine clinical and surgical procedures. Advanced clinical proteomics approaches will be applied to characterize molecular signatures associated with disease onset, progression, and response to treatment. The study seeks to improve the understanding of disease pathophysiology and support the development of novel diagnostic and prognostic biomarkers in ophthalmology.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-24.
Trial Details
NCT Number NCT07500324
Lead Sponsor Fondazione G.B. Bietti, IRCCS
Conditions Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Retinal Detachment
Enrollment 260 participants
Start Date 2024-01-24
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-02